İbrutinib Sonrası Gelişen Dev Ekimoz ve Hematom: Olgu Sunumu.

Ibrutinib, a novel therapeutic agent with increasing use as a highly effective treatment in Chronic lymphocytic leukemia and Mantle cell lymphoma, is associated with a lower incidence of side effects as compared to cytotoxic agents due to its mechanism of action involving targeted monoclonal-antibodies. However, ibrutinib may also cause side effects such as diarrhea, fatigue, fever, nausea, bleeding, cytopenia, or allergic reactions. Bleeding has been reported to occur in more than 50% of the patients, mostly in the form of petechial bleedings. However, life-threatening bleeding may also occur. Herein, we report a case with bleeding occurring after ibrutinib treatment in order to underscore the importance of careful use of this agent in patients with a predisposition for bleeding. [ABSTRACT FROM AUTHOR]